Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follow-up to evaluate the the immunogenicity and safety of GSK Biologicals' MMRV [MMR-varicella zoster virus vaccine] vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals' Priorix [Measles mumps and rubella virus vaccine] and Varilrix [varicella zoster virus vaccine live]

Next Previous
X
Search
Trial Profile

Follow-up to evaluate the the immunogenicity and safety of GSK Biologicals' MMRV [MMR-varicella zoster virus vaccine] vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals' Priorix [Measles mumps and rubella virus vaccine] and Varilrix [varicella zoster virus vaccine live]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Measles mumps and rubella virus vaccine; Varicella zoster virus vaccine live
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 05 Feb 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 14 Dec 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top